Evidence map›Paper›PMID 42491490›Full record

ArticleAACE endocrinology and diabetes

Adult Height After Growth Hormone and Aromatase Inhibitor Therapy for Short Stature due to

Daniel Leopoldo Ruiz, Alexandra Delano, Jose Bernardo Quintos

Abstract readCase Reports
In one paragraph

Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Daniel Leopoldo RuizDivision of Pediatric Endocrinology and Diabetes, Rhode Island Hospital/Hasbro Children's Brown University Health, Providence, Rhode Island.
Alexandra DelanoDivision of Pediatric Endocrinology and Diabetes, Rhode Island Hospital/Hasbro Children's Brown University Health, Providence, Rhode Island.
Jose Bernardo QuintosDivision of Pediatric Endocrinology and Diabetes, Rhode Island Hospital/Hasbro Children's Brown University Health, Providence, Rhode Island.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Objective: Aggrecan ( Case Report: A boy was first evaluated at 2 years and 6 months for short stature, had markedly advanced BA by 5 years and 6 months, and a novel heterozygous frameshift Discussion: GH can improve growth velocity, and AIs may delay epiphyseal fusion by lowering estrogen conversion and thus extending the growth window. Our patient's height gain aligns with reported GH responses in Conclusion: This case highlights the potential benefits of combined GH and AI therapy in managing short stature in patients with

Indexed as

ACANaromatase inhibitorbone age advancementgrowth hormone therapyshort stature

Identifiers

PMID42491490
PMCPMC13377873

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.